Sub Heading

Clinical Trials Details

A Phase 3 Study of Front-Line Platinum Doublet Therapy with Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p. G12C Positive Advanced/Metastatic NSCLC (CodeBreak 202)

IRB Protocol Number
Amgen 20190341

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: 

Men or women, ages 18 and older, with locally advanced or metastatic non-squamous cell NSCLC positive for KRAS p.G12C mutation, negative for PD-L1 expression, and have no history of anticancer treatment in metastatic setting.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.